SIT PHARMA acquires OSTIDIL-D3 and KEFORAL
SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL
SIT Pharma acquires DERINOX® for France market
SIT Pharma is pleased to announce the acquisition of DERINOX® from Therabel Lucien Pharma Sas
SIT Pharma acquires MIZOLLEN® for France market
SIT Pharma is pleased to announce the acquisition of MIZOLLEN® from THERABEL HEALTHCARE LIMITED
SIT Pharma acquires DINTOINA
The acquisition of DINTOINA confirms our will to grow our Italian portfolio in CNS area with essential and well know products and to maintain and assure, to patients and HCP’s, the therapeutic continuity
Now online Centellase website
Centellase has a new strategic visual and a new claim: “Ci prendiamo cura della tua bellezza” (We take care of your beauty).
SIT acquires SULMETIN fom Sanofi
SIT Group is pleased to announce the acquisition of established product SULMETIN from Sanofi, as a result of the agreement signed on November 8, 2022.
SIT acquires POTASION from Sanofi
SIT Group is pleased to announce the acquisition of Potasion brand from Sanofi, as a result of the agreement signed on November 8, 2022.
SIT acquires NATIFAR and NATIMED from Laboratorios BIAL
SIT Group is pleased to announce the acquisition of Natifar and Natimed brands from Laboratorios BIAL, a Spanish affiliate of BIAL Group (BIAL), as a result of the agreement signed on October 25th, 2022.
Spot TV Trofodermin “Per Ripartire Velocemente” 2020
The new Trofodermin TV spot is now on air.
New launch: Coryfin C Senza Zuccheri Miele E Zenzero
Laboratorio Farmaceutico SIT is pleased to announce the release of the new Coryfin C senza zuccheri Miele e Zenzero.